ClinicalTrials.gg
RecruitingNCT07475286Updated Oct 22, 2026

Combined Systemic and Intraperitoneal Chemotherapy for Synchronous Gastric and/or Gastroesophageal Peritoneal Carcinomatosis

A Phase 2 interventional study of Cisplatin and Mitomycin C in Synchronous Gastric Peritoneal Carcinomatosis and Gastroesophageal Peritoneal Carcinomatosis, sponsored by Mohammad Haroon Asif Choudry. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Mohammad Haroon Asif Choudry · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Oct 22, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies testing cisplatin in Peritoneal Neoplasms — 4 open to participants now, 6 under way, none of them phase 3. Cisplatin · Peritoneal Neoplasms.

Planned enrollment
9th of 14
22 · median 27
Started
2026
the only one that year
Phase 2
8 of 14
2 open now
Registered
14th of 14
by date
Lead sponsor
1 of 14
Mohammad Haroon Asif Choudry

Among the 14 studies testing cisplatin in Peritoneal Neoplasms, this one is the 9th largest by planned enrollment, is the only one that started in 2026, is one of 8 in phase 2, and was the 14th registered.

Peritoneal Neoplasms

249 studies on the registry are indexed under Peritoneal Neoplasms; 54 are open to participants now.

Browse Peritoneal Neoplasms studies →

Open to participants now

4 of the 14 studies testing cisplatin in Peritoneal Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About cisplatin

Cisplatin: first FDA approval 1978 (PLATINOL-AQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 48 Peritoneal Neoplasms studies recruiting now, 34 (71%) set no upper age limit and 8 (17%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing cisplatin in Peritoneal Neoplasms, or all of them as a file.
02

Study summary

This trial will administer laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) to patients with peritoneal carcinomatosis from gastric cancer (GPC) who are receiving standard of care systemic chemotherapy.

Read the detailed description

Patients with peritoneal carcinomatosis from gastric cancer (GPC) have dismal oncologic outcomes, with median survival duration of 6-12 months and 2-year overall survival rate of \< 10%. Despite advancements in systemic therapy, survival remains poor and most patients succumb to the disease within 4-11 months following diagnosis. Therefore, there is a substantial need for novel treatment strategies to improve oncologic outcomes in GPC. The primary intervention is the addition of iterative laparoscopic HIPEC to the ongoing standard systemic chemotherapy regimen (or at least the backbone regimen), based on discussion with their treating medical oncologist. Laparoscopic HIPEC will be performed using a combination of cisplatin (100 mg/m2) and mitomycin C (30 mg total, administered in 2 divided doses of 15 mg each, 45 minutes apart), in 3-liters of normal saline perfusate, at 42°C for 90 minutes, with continuous manipulation of the abdomen to ensure even distribution. Systemic chemotherapy will be administered every two weeks while laparoscopic HIPEC procedures will be performed every 6 weeks in place of the scheduled biweekly systemic therapy cycle. The trial will include a maximum of 3 laparoscopic HIPEC procedures.

03

Conditions studied

  • Synchronous Gastric Peritoneal Carcinomatosis
  • Gastroesophageal Peritoneal Carcinomatosis

Browse trials for

Keywords

  • Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven, synchronous gastric and/or gastroesophageal junction (Siewert 3) adenocarcinoma with either positive peritoneal cytology (micPC) or macroscopic carcinomatosis (macPC) (stage IV), diagnosed by imaging or laparoscopy or laparotomy.
  • Patients must be 18 years of age or older at time of .
  • performance status of ≤ 2*

    *Note: ECOG PS of 2 is allowed only if debilitation is caused by the gastric cancer and not by other comorbidities.

  • Must have normal organ and marrow function following completion of 4-6 months systemic therapy and prior to enrollment as assessed on basic laboratory tests:

≥ 8.0 g/dL Leukocytes ≥ 3,000/mcL ≥ 1,500/mcL count ≥ 100,000/mcL Total \< 2mg/dl (SGOT) ≤ 2.5 X institutional (ULN) ALT (SGPT) ≤ 2.5 X institutional ULN Serum creatinine within normal institutional limits

  • Patient should have a of >6 months per the discretion of the treating surgical oncologist and/or medical oncologist in relation to comorbidities and volume of disease.
  • Patients must have received at least 4 months (maximum 6 months) of 1st or systemic therapy at the discretion of the treating medical oncologist and/or surgical oncologist and exhibit no evidence of extraperitoneal disease progression prior to enrollment.
  • Patients with stable oligometastatic liver only (≤ 3 lesions, each \< 3 cm in maximum dimension), ovarian-only metastases, or lung-only metastases (≤ 5 lesions, each \< 1 cm) that are amenable to curative intent surgical resection and/or thermal ablation and/or SBRT will be eligible for enrollment.
  • Sexually active fertile subjects and their partners must agree to use highly effective method of prior to study entry and during the course of the study. An additional contraceptive method, such as a barrier method (e.g., condom), is required. In addition, men must agree not to donate sperm and women must agree not to donate eggs (ova, oocyte) for the purpose of reproduction during these same periods.
  • Female subjects of must not be pregnant or breastfeeding at screening. Female subjects are considered to be of childbearing potential unless one of the following criteria is met:
  • Permanent sterilization (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or documented status (defined as 12 months of amenorrhea in a woman > 45 years-of-age in the absence of other biological or physiological causes.) Note: Documentation may include review of medical records, medical examination, or medical history interview by study site staff.
  • Must have the ability to understand and the willingness to sign a written informed consent document.
  • Must be able to read and write in English.

Exclusion criteria

Exclusion Criteria:

  • Patients with MSI-H tumors, dMMR, TMB > 30, CPS > 40, POL-E mutation, Claudin 18.2 positive tumors, BRAFV600E, RET fusions, -neu (3+ on IHC) or positive on FISH will be excluded.
  • Extensive retroperitoneal lymph node involvement not amenable to surgical resection during gastrectomy.
  • Recurrent large or small bowel obstruction attributable to the cancer (except for gastric outlet obstruction).
  • Prior abdominal surgeries that preclude safe and effective laparoscopy/laparoscopic HIPEC.
  • Significant ascites requiring repeated drainage for symptomatic relief.
  • Other within the preceding 3 years (except for non-melanoma skin cancer, early-stage prostate cancer, or curatively treated cervical cancer in-situ).
  • Patients should have recovered to baseline from any adverse events from prior treatment.
  • Has acute or chronic active and C virus infection or known history of untreated hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) or known active virus (HCV) (defined as HCV RNA [qualitative]) or infection (see note).

Note: No testing for Hepatitis B, Hepatitis C, or HIV is required unless mandated by local health authority or clinically indicated.

Note: Participants with a history of HIV infection are considered eligible if are ≥ 350 cells/µL and the patient has had no opportunistic infections in the last 12 months.

Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (estimated)

Study arms

  • Experimental
    Hyperthermic intraperitoneal chemotherapy (HIPEC)

    Combination of cisplatin (100 mg/m\^2) and mitomycin C (30 mg total, administered in 2 divided doses of 15 mg each, 45 minutes apart) in 3-liters of normal saline perfusate at 42°C for 90 minutes, with continuous manipulation of the abdomen to ensure even distribution.

    Drug: Cisplatin · Drug: Mitomycin C

Interventions

  • Cisplatin interferes with DNA replication, which kills the fastest proliferating cells.

  • DrugMitomycinStudies of MitomycinMitomycin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A drug that slows down the growth of cancer cells by making them less able to create the DNA, RNA, and proteins they need to multiply.

06

What researchers measure

Primary outcomes

  1. 1-year Progression-free Survival (PFS)

    The proportion of patients alive without progression at one year from the date of the first laparoscopic HIPEC treatment. Per RECIST v1.1, Progressive Disease is defined as ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of ≥5 mm. The appearance ≥1 new lesion(s) is considered progression.

    Time frame: At 1 year

Secondary outcomes

  1. Treatment-related Adverse Events

    Frequency and severity (grade) of adverse events (AE) related to study treatment per CTCAE v5.0.

    Time frame: Up to 5 years

  2. Progression-free Survival (PFS)

    Median time from first laparoscopic HIPEC procedure to progression or death from any cause. Per RECIST v1.1, Progressive Disease is defined as ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of ≥5 mm. The appearance ≥1 new lesion(s) is considered progression.

    Time frame: Up to 5 years

  3. Overall Survival (OS)

    Median time from first laparoscopic HIPEC procedure to death from any cause.

    Time frame: Up to 8 years

  4. Objective Response Rate (ORR)

    ORR is defined as the proportion of patients achieving a complete response (CR) or partial response (PR). Per RECIST v1.1, Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (target or non-target) with reduction in short axis to \<10 mm. Partial Response (PR): ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Up to 5 years

  5. Objective Response Rate (ORR) Peritoneal Cancer Index (PCI)

    ORR per Peritoneal Cancer Index (PCI) score extracted from diagnostic laparoscopy procedures (in all patients), defined as the proportion of patients who achieve a reduction in PCI score. This scoring system quantifies the extent of peritoneal metastases in patients with abdominal cancers. It ranges from 0 to max score of 39, with lower scores indicating less disease burden and better surgical outcomes. The abdomen is divided into 13 regions, each scored from 0 to 3 based on the size and extent of tumor involvement. The total score is the sum of these individual scores, providing a clear picture of the disease's spread.

    Time frame: Up to 5 years

  6. EQ-5D-5L scores

    The EQ-5D-5L self-administered questionnaire captures health status across five key dimensions: Mobility: Ability to walk about; Self-Care: Ability to wash or dress oneself; Usual Activities: Ability to perform usual activities (work, study, housework, family, or leisure activities); Pain/Discomfort: Level of pain or discomfort experienced; Anxiety/Depression: Level of anxiety or depression experienced. A 5-level/point scale is used: 1: No problems, 2: Slight problems, 3: Moderate problems, 4: Severe problems, 5: Extreme problems. Scores from each key dimension are added to yield a total score ranging from 5 to 25. Higher scores indicate worse health status. A Visual Analogue Scale (VAS) is also included: Patients rate their overall health on a scale from 0 (worst imaginable health) to 100 (best imaginable health).

    Time frame: Up to 5 years

  7. Rate of Cytoreductive Surgery (CRS)/HIPEC

    Percentage of patients with unresectable locoregional disease prior to enrollment who undergo CRS/HIPEC.

    Time frame: Up to 5 years

07

Study locations

1 of 1 sites recruiting
  • UPMC Hillman Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
    Recruiting
    • Debra Diecks, RN, BSN · Contactdiecksda@upmc.edu · 412-623-8364
    • Cole Stacy, RN, BSN · Contactcolesl2@upmc.edu · 878-261-6872
    • Haroon Choudry, MBBS, FACS · Principal investigator
    • Samer AlMasri, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Jun 2030, 45 months after the start.

Of 28 phase 2 interventional studies under Peritoneal Neoplasms, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 96. This study's planned 45 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Sep 2026, on Oct 22, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2026
First posted
Mar 16, 2026
StartActual
Sep 29, 2026was Jun 2026
Primary completionEst.
Jun 30, 2030
CompletionEst.
Jun 30, 2034
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jun 12, 2026→Sep 29, 2026
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Start date Jun 12, 2026→Sep 29, 2026

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07475286
Lead sponsor
Mohammad Haroon Asif Choudry
Collaborators
Dr. Samer AlMasri, MD
Responsible party
Mohammad Haroon Asif Choudry (Associate Professor of Surgery, University of Pittsburgh) — Sponsor-investigator
First posted
Mar 16, 2026
Start date
Sep 29, 2026
Primary completion
Jun 30, 2030 (estimated)
Completion
Jun 30, 2034 (estimated)
Last update
Oct 22, 2026

Study contacts

Debra Diecks, RN, BSN
Contact
diecksda@upmc.edu
412-623-8364
Stacy Cole, RN, BSN
Contact
colesl2@upmc.edu
878-261-6872
Haroon Choudry, MBBS, FACS
principal investigator · UPMC Hillman Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cisplatin · Mitomycin

Start the discussion